On October 13, UnitedHealth saw an Intraday Rise of 4.96% in Regular Trading, trading at $389.82/share, with turnover of $7.01 billion.

The move was supported by a clear earnings catalyst: the company reported third-quarter revenue of $112.69 billion, above market expectations near $111.3 billion, while adjusted EPS of $4.69 also exceeded consensus around $4.12-$4.15. UnitedHealth additionally raised its full-year adjusted EPS outlook to at least $20.50 from a prior $19.50-$20.00 range, above market expectations near $19.80-$19.87.

Follow-up management commentary also reinforced sentiment. Executives said medical intensity trends are moderating toward a more stable pattern, though still above historical norms, and indicated the starting point for 2027 EPS should be at the low end of its long-term 13%-16% growth range. The CFO also said consensus 2027 earnings estimates may be too low, helping explain why the stock outperformed most managed-care peers during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)